Minor
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
Registry marked status Unknown (sponsor has not verified the record since Jul 2024); last known: Not Yet Recruiting
Hao ZengPhase 2 NCT06523049 Registry history of NCT06523049 on ClinicalTrials.gov (opens the registry)
Changed